DR. DARRELL J. YAMASHIRO

Plain English
This study looked at a new approach to treating high-risk neuroblastoma, a serious childhood cancer, by combining high-dose radiation therapy with immunotherapy. The researchers found that this combination significantly slowed tumor growth and extended the survival of mice with the disease, noting a marked increase in protective immune cells within the tumors. This is important because many patients still have a poor outlook with existing treatments, and new strategies could improve their chances of survival. Who this helps: This research benefits children with high-risk neuroblastoma.

Plain English
This study focused on a type of aggressive cancer called neuroblastoma, especially in patients with stage 4 disease. Researchers found that a protein called ATF5 is often present in high levels in these patients, and high ATF5 levels are linked to worse outcomes. By blocking ATF5, tumor growth and spread to areas like the bone marrow and liver were significantly reduced, showing ATF5's role in helping cancer cells survive and spread. This finding highlights the potential of targeting ATF5 as a new treatment strategy for neuroblastoma. Who this helps: This helps patients with advanced neuroblastoma and their doctors.

Plain English
This study looked at a specific type of skin tumor called pigmented epithelioid melanocytoma (PEM) and identified a new genetic change involving a protein known as PRKCB. The researchers found that this PRKCB fusion can help in diagnosing PEM, which is crucial because it can sometimes be confused with other similar tumors. This matters because accurate diagnosis can lead to better treatment decisions for patients suffering from this type of skin tumor. Who this helps: This helps patients with pigmented epithelioid melanocytoma by improving diagnosis and treatment options.

Plain English
A teenager with liver cancer received immune checkpoint inhibitor therapy (anti-PD1) to shrink the tumor before a liver transplant. Despite concerns that this drug could trigger severe rejection after transplant, the graft remained stable and the patient did well. This case offers early evidence that checkpoint inhibitors may be safely bridged to transplantation in carefully selected pediatric patients.

Plain English
This study explored how high-dose radiation therapy (HDRT) affects a protein called Notch1 in the blood vessels of tumors. When human endothelial cells (which line blood vessels) were exposed to radiation doses of 8 Gy or higher, Notch1 levels increased significantly, and tumors treated with 12 Gy showed a much higher presence of Notch1 compared to lower doses. These findings indicate that high doses of radiation may help tumors resist damage, and combining this treatment with a Notch blocker led to more destruction of tumor blood vessels. Who this helps: This research benefits cancer patients by suggesting more effective treatment methods for tumors.

Plain English
This study looked at a patient with acute lymphocytic leukemia who developed widespread fungal infections due to a type of fungus called Trichosporon asahii, despite receiving antifungal treatment. The patient showed various skin nodules that appeared to be a fungal infection, which were confirmed through special lab tests. Recognizing this specific fungal infection is important because it impacts how doctors treat patients with weakened immune systems. Who this helps: This benefits patients with weakened immune systems, particularly those undergoing treatment for blood cancers.

Plain English
This study looked at pediatric liver tumors and found that many tumors previously classified as a type of liver cancer called small cell undifferentiated hepatoblastoma (SCUD-HB) are actually a more aggressive tumor called malignant rhabdoid tumor (MRT). Out of the six cases studied, four were wrongly labeled as SCUD-HB, highlighting a misclassification issue. It’s important to change the classification because the treatments for SCUD-HB do not work on MRT, which can lead to worse outcomes for patients. Who this helps: This helps doctors and patients by improving tumor diagnoses and treatment options.

Plain English
This study looked at a specific skin condition called erythema nodosum that appeared in a child taking everolimus, a medication for tuberous sclerosis complex. The case highlights this rare side effect of the treatment, emphasizing the need for doctors to be aware of and manage skin problems that can arise. Understanding this can help ensure patients receive better overall care while on this medication. Who this helps: This helps patients with tuberous sclerosis and their doctors.

Plain English
This study focused on a protein called TFAP4, which is linked to a type of cancer known as MYCN-amplified neuroblastoma. Researchers found that lowering the levels of TFAP4 can slow down the growth of cancer cells both in lab tests and in mouse models, indicating that patients with this type of cancer might have better outcomes if TFAP4 is targeted in treatment. Specifically, patients with high TFAP4 levels tended to have poorer survival rates. Who this helps: This research benefits neuroblastoma patients, especially those with MYCN amplification.

Plain English
This case report describes an 18-month-old girl with three simultaneous rare conditions — autosomal recessive polycystic kidney disease, Caroli syndrome, and hepatoblastoma — successfully treated with surgical resection alone without chemotherapy. Nine years later she remained tumor-free with stable kidney function. The case adds to a limited literature on managing concurrent pediatric liver tumors and cystic kidney disease.

Plain English
This study investigated how high doses of radiation therapy affect blood vessels in neuroblastoma tumors, a type of cancer that primarily affects children. Researchers found that a single high dose of 12 Gy radiation led to a 63% decrease in blood volume within the tumor just 6 hours after treatment, while a lower dose of 2 Gy only reduced blood volume by 24%. This is significant because it shows that high-dose radiation can quickly disrupt tumor blood flow, which may make the tumor more vulnerable to other treatments. Who this helps: This benefits patients with high-risk neuroblastoma by improving treatment strategies.

Plain English
This study looked at a protein called HAUSP that helps stabilize another protein, N-Myc, which is important in neuroblastoma, a type of cancer. Researchers found that high levels of HAUSP are linked to worse outcomes for patients with neuroblastoma, as it increases N-Myc activity. They also discovered that blocking HAUSP could slow down tumor growth in lab models, suggesting it might be a promising treatment for patients with tumors that have high levels of N-Myc. Who this helps: This research benefits patients with neuroblastoma, especially those with high N-Myc levels.

Plain English
This study focused on a rare type of cancer in a teenager called poorly differentiated carcinoma. Researchers discovered several genetic mutations in the tumor, including a new variant linked to Gardner syndrome. They found that certain treatments targeting specific genetic changes, like the drug temsirolimus, showed promising results in lab models, suggesting a new potential therapy for this type of cancer. Who this helps: This benefits children with rare tumors and their doctors by providing new treatment options based on genetic testing.

Plain English
This study focused on using advanced genetic testing, called next generation sequencing (NGS), to improve care for children with difficult-to-treat cancers and blood diseases. Among 101 patients tested, 38% had identifiable genetic changes that could guide treatment, but only 16% actually received therapies tailored to those changes. In total, 66% of cases revealed important information that affected clinical decisions, helping to avoid ineffective treatments and make accurate diagnoses. Who this helps: This research benefits pediatric patients with cancer and their doctors by providing more personalized treatment options.

Plain English
This study looked at the Notch pathway, which is important in how tumors grow, and found that blocking it actually increased the spread of cancer to the liver from neuroblastoma and breast cancer. When researchers used a Notch1 decoy to inhibit its activity, they saw a sharp rise in liver metastases, with significant growth noted in mice lacking Notch1, indicating its role in preventing cancer spread in the liver. These findings highlight the risks of therapies targeting Notch because they could inadvertently promote cancer spread instead of helping to control it. Who this helps: This helps researchers and doctors understand the complexities of treating cancers and the potential downside of targeting the Notch pathway.

Plain English
Researchers studied how certain drugs could protect nerve cells from damage while also affecting cancer cells. They found that a drug called ciclopirox not only shielded nerve cells from stress but also reduced cancer cell growth without harming the nerve cells at the same concentrations. Other similar drugs showed protective effects on nerves while killing cancer cells as well. This research is important because it indicates that certain therapies can help treat neurological diseases without significantly increasing the risk of promoting cancer. Who this helps: This helps patients with neurological diseases and cancer by offering potential new treatment options.

Plain English
The study looked at how two pathways in tumors, Notch and VEGF, work together to promote the growth of blood vessels that feed tumors. Researchers found that blocking both pathways at the same time led to more blood vessel shrinkage and increased death of cells that support these vessels, even though it didn’t reduce the tumor size itself. This is important because it shows that using both treatments together could be a more effective way to lower the viability of tumors than using either treatment alone. Who this helps: This helps patients undergoing cancer treatment by offering potential new strategies for slowing tumor growth.

Plain English
This study focused on using special bubbles combined with DNA to deliver genetic material directly to solid tumors in mice. Researchers created a new type of bubble that carried DNA and found that when ultrasound targeted these bubbles to tumors, they resulted in over 10 times more gene activity in the tumor compared to untreated areas and showed a more than 40-fold increase in DNA expression in tumor tissue versus non-targeted tissue. This research is significant because it demonstrates a promising new method for directly delivering genes to tumors, which could improve cancer treatments. Who this helps: This helps cancer patients by potentially improving the effectiveness of gene therapies.

Plain English
This study looked at how well a noninvasive imaging technique called diffuse optical tomography (DOT) can quickly show how tumors respond to a cancer drug called bevacizumab (BV). Researchers found that one day after treatment, there was a significant drop in total hemoglobin levels in tumors that responded to the drug—specifically, a decrease of 40% in certain tumor types—while tumors that did not respond showed no change. This method of monitoring could help doctors adjust treatments more effectively, reducing side effects and costs while improving patient outcomes. Who this helps: This benefits patients undergoing cancer treatment by providing a way to tailor therapies to individual responses.

Plain English
This study looked at how well a specific cancer treatment called bevacizumab works by using a special ultrasound technique called contrast-enhanced ultrasound imaging (CEUS). Researchers found that this ultrasound method could detect changes in blood flow in tumors treated with the drug, showing that it stopped blood volume from increasing in tumors that responded to the treatment. This method can identify whether the treatment is working as early as three days after starting therapy, which is important for quickly adjusting patient care if needed. Who this helps: This helps patients with cancer by allowing doctors to monitor treatment effectiveness more quickly and make better treatment decisions.

Plain English
This study looked at how certain genes behave in glioblastoma, a type of brain cancer, and how this relates to how long patients stay cancer-free after treatment. Researchers found that patients with lower levels of a specific gene signature associated with cell changes (called mesenchymal transition) had a longer time before their cancer returned—specifically, a significance level of P = 3×10^(-7). This finding matters because it suggests that targeting this gene expression could lead to better treatment outcomes for glioblastoma patients. Who this helps: This helps glioblastoma patients and their doctors in understanding treatment effectiveness and potential improvements in therapy.

Plain English
Researchers studied aflibercept, a drug aimed at treating children with hard-to-treat solid tumors. They found that the safe maximum dose for children is 2.5 mg per kg of body weight, which is lower than the dose recommended for adults. At this dose, some children showed no progression of their tumors for more than 13 weeks, indicating it may work for some patients. Who this helps: This research benefits children with difficult-to-treat cancers and their doctors.

Plain English
This research focuses on a rare case of colon cancer in a 13-year-old girl who experienced abdominal pain for 11 months before receiving a correct diagnosis. The delayed diagnosis happened because her symptoms were not clearly linked to cancer, highlighting a gap in awareness for such cases. This is important because it shows that even young patients can develop colon cancer, which often goes unrecognized due to the rarity of the disease in children. Who this helps: This information benefits patients, doctors, and parents by raising awareness about the possibility of colon cancer in younger age groups.

Plain English
This research studied how blocking a protein called vascular endothelial growth factor (VEGF), which is used to treat cancer, works better when combined with a drug that inhibits another protein called COX-2. The researchers found that this combination significantly reduced the spread of cancer to the lungs in a pediatric cancer model, while not affecting the growth of the primary tumor itself. This matters because it highlights a way to specifically prevent metastasis, which is a major challenge in cancer treatment. Who this helps: This benefits pediatric cancer patients by potentially reducing the chances of cancer spreading in their bodies.

Plain English
This research reviews the development of drugs that block a pathway involved in blood vessel formation, which is important for treating solid tumors in children. The study found that these drugs can have different side effects in children compared to adults, particularly affecting the heart, bones, and hormones, making their safety crucial for young patients. It emphasizes the need for careful testing to understand the long-term health impacts of these treatments before they are widely used in children with cancer. Who this helps: This helps children with cancer and their doctors by ensuring safer treatment options.

Plain English
This study examined how human cancer cells behave in living organisms, specifically looking at the factors that help them move and invade other tissues. Researchers found that these cancer cells express a unique set of genes related to invasion, including a key factor called Slug, and this pattern was consistent across different types of cancer, highlighting its importance in cancer growth and spread. Understanding these cancer cell behaviors can lead to better diagnostic tools and treatments to limit their ability to invade and spread. Who this helps: This benefits patients by potentially leading to more effective cancer treatments.

Plain English
This study focused on a new imaging technique that helps visualize specific substances (chromophores) in biological tissues, such as those found in tumors. Researchers found that this new method can reconstruct images up to 15 times faster and more accurately than previous techniques. This is important because it can lead to better diagnosis and treatment planning in medical settings. Who this helps: Patients with tumors and doctors involved in their care.

Plain English
This research paper highlights the contributions of three doctors—James Homer Wright, William Pepper, and Robert Hutchison—who helped define neuroblastoma over a century ago. Wright identified the tumor as originating from primitive nerve cells and noted its specific cell patterns, while Pepper and Hutchison documented how the disease spreads differently in infants and older children. These early findings laid the groundwork for better treatments and improved patient outcomes in neuroblastoma care today. Who this helps: This helps patients with neuroblastoma and their doctors by providing a historical context for treatment advancements.

Plain English
This study looked at how a protein called angiopoietin-1 (Ang-1) affects blood vessel and tumor growth when a common cancer treatment, VEGF blockade, is used. The researchers found that during VEGF treatment, increasing Ang-1 helped tumors survive and grow by improving blood vessel function and preventing low oxygen levels in the tumors. This finding is important because it highlights the need to consider how Ang-1 can influence treatment outcomes in patients receiving VEGF inhibitors, potentially leading to better treatment strategies in the future. Who this helps: This helps cancer patients receiving VEGF inhibitors.

Plain English
This study looked at a 6-year-old child with liver cancer who experienced serious side effects after taking a cancer drug called bevacizumab. The child developed high blood pressure, seizures, and brain changes, but these issues fully resolved with proper treatment to control blood pressure. Understanding and managing the risks of these side effects is important as more children receive this medication. Who this helps: This helps doctors and pediatric patients undergoing treatment with bevacizumab.

Plain English
This study looked at children with a type of cancer called neuroblastoma, particularly those with a bad prognosis due to a genetic change known as MYCN amplification. Researchers tested whether blocking a protein involved in blood vessel growth (VEGF) could slow tumor growth and disrupt blood supply. They found that this treatment did not stop tumor growth, but did lead to slight increases in tumor hypoxia and activated alternative mechanisms for blood vessel formation, showing that these tumors can adapt even when VEGF is blocked. Who this helps: This research benefits doctors and researchers working on new treatments for aggressive neuroblastoma in children.

Plain English
This paper looks at the link between neuroblastoma, a type of cancer, and opsoclonus-myoclonus syndrome (OMS), a rare neurological disorder. Researchers found that while OMS occurs in only 2-3% of children with neuroblastoma, up to 50% of children with OMS may actually have neuroblastoma. Almost all affected children survive, suggesting that OMS could be caused by an autoimmune response rather than cancer spreading, although many still face ongoing neurological and developmental challenges. Who this helps: This helps children with neuroblastoma and OMS and their doctors in understanding the connection between these conditions.

Plain English
This study looked at a rare type of kidney tumor called clear cell sarcoma of the kidney (CCSK) in children. Researchers found that the tumor has a unique structure with specific patterns of blood vessel development, which may help identify new ways to treat it. Understanding these blood vessel patterns is important for developing targeted therapies that could improve outcomes for affected children. Who this helps: This helps doctors and patients dealing with clear cell sarcoma of the kidney.

Plain English
This study looked at a drug called bevacizumab, given to children with hard-to-treat solid tumors, to find out the highest safe dose and any side effects. They treated 21 kids, with an average age of 13, and found that the drug was mostly well tolerated, with no severe side effects reported, though some patients experienced mild reactions like rash or low blood cell counts. This is important because it shows that bevacizumab can be safely used in pediatric patients, paving the way for more research and potentially better treatments for children with tough cancers. Who this helps: This helps children with cancer and their doctors.

Plain English
Researchers studied how blocking a protein called VEGF, which helps tumors grow blood vessels, affects advanced liver cancer in children. They found that while the initial treatment caused tumors to shrink and blood vessels to disappear, over time the tumors managed to recover their blood supply and continue growing. This is important because it shows how tumors adapt to treatment, highlighting the need for better strategies in cancer care. Who this helps: This helps doctors and researchers working on more effective cancer treatments for children.

Plain English
This study looked at how blocking a specific part of the Notch signaling pathway affects blood vessel development in tumors. Researchers created a form of the Notch1 receptor that can interfere with this signaling and found that it stopped the growth of new blood vessels in tumors in mice, reducing tumor growth significantly. In one test with mouse tumors, using the Notch1 decoy led to a notable decrease in blood vessel formation and overall tumor size. Who this helps: This benefits cancer patients by providing a potential new treatment approach to limit tumor growth and blood vessel formation.

Plain English
This study looked at how a specific enzyme called COX-2 affects the formation and stability of blood vessels in tumors, specifically in Wilms' tumor, a type of kidney cancer. Researchers used a COX-2 inhibitor called SC-236 and found that it significantly reduced tumor growth by 78% after four weeks and 55% after five weeks, along with causing the blood vessels to be poorly formed and unstable. This is important because it highlights how targeting COX-2 could improve cancer treatments by making tumor blood vessels weaker and less functional. Who this helps: This helps cancer patients by potentially providing a new treatment approach to slow down tumor growth.

Plain English
This research studied the genetic changes in Wilms' tumors, a type of kidney cancer in children, to better understand how they form. The scientists found that sporadic Wilms' tumors often lost certain genetic markers (called loss of heterozygosity) on several chromosomes, particularly on chromosome 11p15, while tumors linked to syndromes usually did not show these changes. They also discovered that changes in DNA methylation were more common in sporadic cases, and these changes occurred early in tumor development, which may help in distinguishing between different types of Wilms' tumors. Who this helps: This helps doctors and researchers by providing insights into the differences in tumor behavior, aiding in better diagnosis and treatment strategies for patients.

Plain English
This study looked at a type of stem cell transplant called reduced intensity allogeneic stem cell transplantation (RI AlloSCT) in children and young adults, focusing on how well it works and how safe it is. Researchers found that out of 21 recipients, 24% experienced graft failure, but 85% achieved over 50% donor cell presence (chimerism) soon after the transplant. These findings are important because they show that this transplant method can be an effective option for young patients with certain conditions, even when using unrelated donor stem cells. Who this helps: Patients with blood disorders needing stem cell transplants.

Plain English
This study looked at what happens to blood vessels in tumors that start to grow again after treatment aimed at stopping their blood supply. Researchers found that after blocking blood vessel growth for a while, the tumor blood vessels became larger and were more active, which helped the tumors to grow back. Specifically, they noted that these remodeled vessels had significant changes, including a notable increase in their size and new types of cells recruited to support their growth. Who this helps: This helps doctors understand how to better manage tumor growth and improve treatment strategies for patients with certain types of cancers.

Plain English
This study looked at different types of vascular growths, especially hemangiomas, to understand their biological markers and why some shrink over time while others do not. The researchers found that a specific marker called placental growth factor (PIGF) was significantly higher in common hemangiomas that shrink compared to those that do not shrink at all, indicating it could help identify which growths are likely to resolve naturally. Understanding these differences matters because it could lead to better predictions on how these tumors will behave, guiding treatment decisions for patients. Who this helps: This helps doctors and patients dealing with various vascular growths, particularly hemangiomas.

Plain English
This study focused on TNP-470, a compound thought to stop blood vessel growth in tumors, particularly looking at its effects on Wilms tumors in a lab model. Researchers found that while TNP-470 reduced tumor growth by 83% after 5 weeks, it did not decrease blood vessel formation; instead, it increased tiny new blood vessels. This matters because it shows that TNP-470 works primarily by killing tumor cells rather than blocking the growth of blood vessels, which is a new understanding of how this treatment could work. Who this helps: This helps doctors and researchers who are developing treatments for cancer patients.

Plain English
This study looked at how blocking a protein called VEGF affects the growth of early-stage Wilms tumors, a type of kidney cancer found in children. The researchers found that treatment with a VEGF-blocking drug led to tumors that were about 93% to 99% smaller, and the spread of cancer to the lungs was reduced significantly. This is important because it shows that blocking VEGF can drastically slow down tumor growth and potentially improve treatment outcomes for patients. Who this helps: This helps patients with early-stage Wilms tumors and their doctors in finding more effective treatments.

Plain English
This study looked at why some cancer patients do not respond to antiangiogenic therapy, which is designed to block blood vessel growth in tumors. Researchers discovered that when patients developed resistance, it was linked to changes in their blood vessels and an increase in certain growth factors, specifically PDGF-B and angiopoietin-1. Understanding these changes is crucial for scientists to improve treatment effectiveness and help more patients respond to therapy. Who this helps: This benefits cancer patients who are receiving antiangiogenic treatments.

Plain English
This study looked at how blocking a protein called VEGF, which helps create blood vessels, can shrink existing tumors and stop cancer from spreading. Researchers found that using a strong VEGF blocker led to the disappearance of blood vessels in tumors, causing significant tumor shrinkage, including small metastases in the lungs. This is important because it shows a new way to treat advanced cancers that have already spread. Who this helps: This helps patients with advanced, metastatic cancer who need more effective treatment options.

Plain English
The study looked at how blocking a specific protein called her2/neu affects the growth of Wilms tumors, a type of kidney cancer in children. Researchers found that blocking her2/neu reduced the levels of a substance called VEGF, which promotes blood vessel growth in tumors, by about the same amount in the tumors that overexpress her2/neu. However, it did not significantly change the distribution of another protein, HIF-1alpha, which is also involved in tumor growth. Who this helps: This research could benefit doctors treating children with Wilms tumors, especially those with high levels of her2/neu.

Plain English
This study looked at how thalidomide affects blood vessel growth in neuroblastoma, a common childhood cancer that often spreads early. The researchers found that while thalidomide didn’t greatly reduce tumor size, it did significantly lower the number of blood vessels in tumors by more than 86% (p<0.004). This is important because reducing blood supply can help slow cancer growth, and new treatments are needed for children with this aggressive type of cancer. Who this helps: This helps children with neuroblastoma and their doctors looking for better treatment options.

Plain English
This study looked at how a protein called her2/neu affects the growth of Wilms' tumors, which are kidney cancers that mostly occur in children. The researchers found that when they blocked the her2/neu protein in tumors that expressed it, the tumors grew slower and had fewer blood vessels forming, indicating less angiogenesis. This is important because it shows that targeting her2/neu could be a potential treatment for certain Wilms' tumors, which could lead to better outcomes for patients. Who this helps: This helps patients with her2/neu-expressing Wilms' tumors.